[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363978-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363978-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","efficacy-and-safety-of-immunotherapy-in-driver-mutation-negative-advanced-non-small-cell-lung-cancer-a-systematic-review-and-metaanalysis","Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer - A systematic review and metaanalysis","","Immunotherapy’s effectiveness and safety for advanced non-small cell lung cancer (NSCLC) without identifiable driver mutations remain uncertain. This systematic review and meta-analysis evaluated immunotherapy given as monotherapy or alongside chemotherapy versus chemotherapy alone in patients with advanced driver mutation–negative NSCLC. Searches covered PubMed, Embase, Scopus, and CENTRAL up to December 2024, with protocol registration in PROSPERO. Twenty-three RCTs (n=14,605) showed improved overall survival and progression-free survival with no significant difference in overall adverse events.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-and-safety-of-immunotherapy-in-driver-mutation-negative-advanced-non-small-cell-lung-cancer-a-systematic-review-and-metaanalysis/363978/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-immunotherapy-in-driver-mutation-negative-advanced-non-small-cell-lung-cancer-a-systematic-review-and-metaanalysis/363978.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the systematic review?","Question",{"text":63,"@type":64},"To assess the efficacy and safety of immunotherapy, used alone or with chemotherapy, compared with chemotherapy alone in advanced driver mutation–negative NSCLC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which studies were included in the analysis?",{"text":68,"@type":64},"Randomised controlled trials evaluating immunotherapy (alone or with chemotherapy) versus chemotherapy alone, searched across PubMed, Embase, Scopus, and CENTRAL up to December 2024.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes improved with immunotherapy compared with chemotherapy?",{"text":72,"@type":64},"Immunotherapy significantly improved overall survival and progression-free survival, and also increased objective response rate versus chemotherapy alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363978,1790514704,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Indian J Med Res 164, August 2026, pp 203-219 DOI: 10.25259/IJMR_3200_2025  \nSystematic Review  \nEfficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and metaanalysis  \nJogender Kumar, 1 Shuvadeep Ganguly,2 Parminder Kaur, 1 Alok Raghav, 1 Kirti Pai,1 Jitendra Meena,3 Jagdish Prasad Goyal4 and Jaivinder Yadav1  \n1Department of Pediatrics (Advanced Pediatrics Centre), Postgraduate Institute of Medical Education and Research, Chandigarh, 2Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, 3Department of Pediatrics, All India Institute of Medical Sciences, New Delhi and 4Department of Pediatrics, All India Institute of Medical Science, Jodhpur, Rajasthan, India  \nReceived November 15, 2025; Accepted January 22, 2026; Published August 1, 2026  \nBackground and objectives: Despite substantial research on immunotherapy, its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC) without identifiable driver mutations remain unclear. The objective of this review was to examine the efficacy and safety of immunotherapy, used as monotherapy or alongside chemotherapy, vs. chemotherapy alone in patients with advanced driver mutation–negative NSCLC.  \nMethods: A comprehensive literature search of PubMed, Embase, Scopus, and CENTRAL databases was conducted until December 2024. The protocol was registered in PROSPERO (CRD42024585050). Randomised controlled trials (RCTs) evaluating the efficacy and safety of immunotherapy, either as monotherapy or in combination with chemotherapy, compared with chemotherapy alone, were included. A random-effects meta-analysis was performed. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the GRADE framework.  \nResults: Twenty-three RCTs (n=14605 participants) were included. Immunotherapy (± chemotherapy) significantly improved overall survival [22 RCTs; 14,375 participants, hazard ratio (HR): 0.77; 95% Confidence interval (CI): 0.72-0.83] and progression-free survival (22 RCTs; 14,003 participants, HR: 0.67; 95% CI: 0.58-0.76) compared with chemotherapy alone. The objective response rate was also higher with immunotherapy (23 RCTs; 12,967 participants, RR 1.38, 95% CI: 1.24-1.54) . No statistically significant differences were observed between the groups in terms of overall adverse event rates.  \nInterpretation and conclusions: Immunotherapy, whether administered alone or in combination with chemotherapy, provides significant survival benefits in patients with advanced driver mutation–negative NSCLC.  \nKeywords Immunotherapy; Lung cancer; Metastatic; Mutation; Non-small cell lung cancer  \nLung cancer is the leading cause of cancer-related death worldwide, contributing to about 18% of total cancer mortality.1 Non-small cell lung cancer (NSCLC) constitutes approximately 85% of lung cancer cases, encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and is often diagnosed at an advanced stage when curative options are limited.2  \nAdvances in molecular profiling have identified multiple actionable oncogenic driver mutations in  \nNSCLC, such as EGFR, ALK, and ROS1, and the development of targeted therapies against these alterations has substantially improved survival outcomes.3 However, a considerable proportion of patients lack these mutations, forming a drivermutation-negative subgroup.  \nIn recent years, immune checkpoint inhibitors (ICI) targeting programmed cell death protein 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) have substantially reshaped the  \nHow to cite this article: Kumar J, Ganguly S, Kaur P, Raghav A, Pai K, Meena J, et al. Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis. Indian J Med Res. 2026;164:203-19 . doi: 10.25259/IJMR_3200_2025  ","cbCaik8MgfUW94ly","https://ap.wps.com/l/cbCaik8MgfUW94ly","pdf",838602,17,"English","# Background and objectives\n# Methods\n# Results\n# Interpretation and conclusions\n# Methods (continued)\n## Protocol registration and reporting\n## Eligibility criteria and outcomes","[{\"question\":\"What was the main objective of the systematic review?\",\"answer\":\"To assess the efficacy and safety of immunotherapy, used alone or with chemotherapy, compared with chemotherapy alone in advanced driver mutation–negative NSCLC.\"},{\"question\":\"Which studies were included in the analysis?\",\"answer\":\"Randomised controlled trials evaluating immunotherapy (alone or with chemotherapy) versus chemotherapy alone, searched across PubMed, Embase, Scopus, and CENTRAL up to December 2024.\"},{\"question\":\"What outcomes improved with immunotherapy compared with chemotherapy?\",\"answer\":\"Immunotherapy significantly improved overall survival and progression-free survival, and also increased objective response rate versus chemotherapy alone.\"}]","Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer - A systematic review and metaanalysis | PDF",1790154744,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eda25994ed81c28f3a86e3c1447492b3.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/079eb7d62bf463bc373dfaa151a58040.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/169d93c4ab8004d87e86113b3e23ce2b.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35ebba0003061e3a2728a995bcf65484.webp",980,1268]